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HYALURONIDASE ANID CANCER 
J. J. SAMMUT 
B.Sc., M.D., F.I.C.S: 
In 1968 a paper by the undersigned 
appeared in this Gazette enftled "Cancer: 
an Immune Response Through Cell Evolu-
tion". Immediately afterwards, the emin-
ent onchologist Sir Peter Medawar, found 
time to comment on it in a personal letter. 
He remarked it was very sim'lar in many 
ways to the theory 0;7 the late Professor 
H.N. Green, with which he did not agree 
anyway. 
I have recently gone through Prof. 
Green's last and comprehensive-bock "An 
Immunological Approach To Cancer", 
which I recall having read before 1968 but 
to which I had made no reference because 
with respect. I considered my approach dif-
fered fundamentally from h s. Whilst 
Green's masterly work deals with the 
tumour-cell RE-cell relationship, my own 
armchair theory stipulates that cancer cells 
are ordinary tissue-cells turned immuno-
cyte against carcinogen, the latter being the 
antigen. 
There is now ever-mounting evidence 
that RE-cell immunity towards cancer-cells 
does exist, but paradox' calIy, tumours 
become established even if highly antigenic 
because "tumour-associated antigens "are 
shielded from immunocytes" (Leroy, 1975) 
This is an argument parallel to my own, in 
which I suggested that new tumour-cells, 
acting as immunocytes" are shielded from 
the carcinogen, acting as antigen. Ac-
cording to Burnet's phenomenon of 
"Immune Surveillance", thpL immune system 
constantly detects and destroys any abnor-
mal clones of cells that arise in the body. 
Presumably here the immune system res-
ponds at least as rapidly as the clones deve-
lop. A tumour is "estabrshed" following 
continued carcinogen action, which, by ac-
celerating the speed of growth, relatively 
slows down the immune response. (Bowry, 
1975) Whether my original contention was 
correct or not, i.e. that the tumour-cell itself 
is a form of immunocyte, the fact remains 
that tumour-cells, being independent of any 
growth-controlling influence, undergoyrapid 
mitoses in all directions and at all sites of 
the tumour, peripherally and centrally"here 
produc"ng that compactness of cells which 
is felt clinicaly in an advanced neoplasm as 
deep induration. The cells become so th' ck-
ly packed that intercellular spaces are vir-
tually obliterated. This impenetrab:Iity of 
spaces is possibly what phySically consti-
tutp;s that "shielding" which prevents effec-
tive completion of the immune response, 
even after carcinogE'n is discontinued. 
If this be so, is there any means where-
by these spaces could be widened suffi-
ejlently to facilitate the deep penetration of 
immunocytes and humoral antibodies, the 
neutralisation of tumour cells and their 
eventual elimination? In my first publ" ca-
tion on the subject, mentioned at the begin-
ning of this paper, I had suggested the use 
of a carcinogen-hyaluron'dase combination 
to induce immunological paralysIs of the 
tumour-cell's action against the carcinogflll. 
The enzyme hyaluronidase would act by 
dissolving the "shield" formed by the inter-
cellular connective fssne. Not surpris;ngly, 
the suggestion has remained, as far as I 
know, a ,1olce in the wilderness - after an, 
let's I:ace it, the idea of injecting more car-
cinogen into a' cancer par ent can hardly be 
expected to be taken seriously! 
Over and over again, hyaluronidase 
has been shown to be clinically effective 
and harmless when used for the dispersal of 
bruises and the extravasation of anaesthe-
tics; and also for a'd in the absorption of 
opaque X-~ay material which then concen-
treated in the kidneys within a few minutes 
from the time of injection. This latter ex-
ample shows the rapidity of its absorption 
and universality of its distribution through 
the body. An other instance is the rapid dis-
persal of a facial haematoma after injec-
tion of hyaluron' dase into a site as :lar re-
moved as the buttock. 
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This, then, more than any other, would 
seem to be the mosClikely means for re-
moval of the intercellular barrier or "im-
munological shield". 
The examples given above show the 
way hyaluron' dase acts in certain given 
conditions in an otherwise healthy indivi-
dual. How would it behave in a debilitated 
patient w,·th poor circulation? Would it 
re.ach the tumour site or sites and, once 
there, would it be 'effective in pervading 
and widening the obliterated intercellular 
spaces to the desired degree? The liker-
hoods seems poor, esp'eci.ally with regard to 
the deepest cells. The optimist is left with 
the hope that it would be a' matter of time, 
the peripheral cells b,eing dealt with first, 
before the enzyme and the follow'ng immu-
nocytes and antibodies find their way to the 
deepest recesses. 
The use of carcinogen-hyaluronidase 
combination, as originally suggested, would 
obviously imply previous animal exper'men-
tation, for which this writer has no facili-
ties. With our long clinical experience of 
hyaluronidase on its own, and its harmless-
ness and effectiveness in other fields, woura 
one not be justifi'.ed, scientifically and 
ethically, to enlist its aid in all cases of 
malignancy? There would appear to be no 
reason why the orthodox measures should 
not be continued at the same time. In the 
more debilitated patients an eye would also 
have to be kept on electrolyte balance 
(Bailey & Love, 1971). 
If, in the process, my first contention 
should prove to have some foundation, i.e. 
that hy.aluronidase a;ds cancer cells to dis-
pose of the carcinogen macromolecules, 
there couJd certainly be no objection to this 
donble action. 
Just in case the "practical hypothesis" 
summarised in this short paper should 
a.ctually find a following, a note of warning 
would not be out of place. Should it turn 
out that hyaluronidase does widen int·ercel-
lular tumour spaces to the point of allowing 
entry of RE-cells, might it not, at the same 
time, have the effect of detaching clumps 
of malignant cells and actually predispos'ng 
to metastasis formation? - 'even though, 
one hopes, these cells would be again 
,attacked at their new site(s) of adoption. For 
this reason, initial USe of th' s method would 
have to be confined to 'experimental animals 
with "primary", i.e. non-transplanted, 
tumours or, clinically, to patients who have 
been declared inoperable and are not res-
pond'ng satisfactorily to conventional freat-
ment. Naturally, they would have to be 
made fully aware of the implications be-
fore being asked for their consent. 
On the other hand, it would not be fair 
to expect hyaluronidase to work miracles 
on terminal cases who would die anyway 
even if, so to speak, the entire tumour dis-
appeared spontaneously overnight. 
Over several decades thousands of de-
dicated researchers have been employed 
and millions spent in the all-out war a:gainst 
this cruel scourge we call cancer. The ex-
penditure involved in the trial of just one 
other possible adjuvant and its reiection (or 
acceptance) would surely be negligibl'e. 
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